Literature DB >> 26986818

Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries.

Lorenz Waldmeier1, Ina Hellmann1, Chantal K Gutknecht1, Fabian I Wolter1, Skylar C Cook2, Sai T Reddy2, Ulf Grawunder1, Roger R Beerli1.   

Abstract

In vitro antibody display and screening technologies geared toward the discovery and engineering of clinically applicable antibodies have evolved from screening artificial antibody formats, powered by microbial display technologies, to screening of natural, full-IgG molecules expressed in mammalian cells to readily yield lead antibodies with favorable properties in production and clinical applications. Here, we report the development and characterization of a novel, next-generation mammalian cell-based antibody display and screening platform called Transpo-mAb Display, offering straightforward and efficient generation of cellular libraries by using non-viral transposition technology to obtain stable antibody expression. Because Transpo-mAb Display uses DNA-transposable vectors with substantial cargo capacity, genomic antibody heavy chain expression constructs can be utilized that undergo the natural switch from membrane bound to secreted antibody expression in B cells by way of alternative splicing of Ig-heavy chain transcripts from the same genomic expression cassette. We demonstrate that stably transposed cells co-express transmembrane and secreted antibodies at levels comparable to those provided by dedicated constructs for secreted and membrane-associated IgGs. This unique feature expedites the screening and antibody characterization process by obviating the need for intermediate sequencing and re-cloning of individual antibody clones into separate expression vectors for functional screening purposes. In a series of proof-of-concept experiments, we demonstrate the seamless integration of antibody discovery with functional screening for various antibody properties, including binding affinity and suitability for preparation of antibody-drug conjugates.

Entities:  

Keywords:  Antibody; antibody drug conjugate; discovery; display; mammalian; platform; screen; secretion; therapeutic; transgene; transposition

Mesh:

Substances:

Year:  2016        PMID: 26986818      PMCID: PMC4966844          DOI: 10.1080/19420862.2016.1160990

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  57 in total

Review 1.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

2.  piggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells.

Authors:  Sareina Chiung-Yuan Wu; Yaa-Jyuhn James Meir; Craig J Coates; Alfred M Handler; Pawel Pelczar; Stefan Moisyadi; Joseph M Kaminski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

Review 3.  Mesothelin-targeted agents in clinical trials and in preclinical development.

Authors:  Ronan J Kelly; Elad Sharon; Ira Pastan; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

4.  DNA transposons: nature and applications in genomics.

Authors:  Martín Muñoz-López; José L García-Pérez
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

Review 5.  Construction of cDNA libraries in vaccinia virus.

Authors:  Ernest S Smith; Shuying Shi; Maurice Zauderer
Journal:  Methods Mol Biol       Date:  2004

6.  The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Authors:  Alan F Wahl; Kerry Klussman; Jennifer D Thompson; Judy H Chen; Leigh V Francisco; Grant Risdon; Dana F Chace; Clay B Siegall; Joseph A Francisco
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

7.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 8.  Mammalian cell display and somatic hypermutation in vitro for human antibody discovery.

Authors:  David J King; Peter M Bowers; Marilyn R Kehry; Robert A Horlick
Journal:  Curr Drug Discov Technol       Date:  2014-03

9.  Targeting malignant B cells with an immunotoxin against ROR1.

Authors:  Sivasubramanian Baskar; Adrian Wiestner; Wyndham H Wilson; Ira Pastan; Christoph Rader
Journal:  MAbs       Date:  2012-04-26       Impact factor: 6.440

10.  Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

Authors:  Jiahui Yang; Sivasubramanian Baskar; Ka Yin Kwong; Michael G Kennedy; Adrian Wiestner; Christoph Rader
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

View more
  10 in total

1.  Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Authors:  Junpeng Qi; Xiuling Li; Haiyong Peng; Erika M Cook; Eman L Dadashian; Adrian Wiestner; HaJeung Park; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

2.  Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

Authors:  Haiyong Peng; Thomas Nerreter; Jing Chang; Junpeng Qi; Xiuling Li; Pabalu Karunadharma; Gustavo J Martinez; Mohammad Fallahi; Jo Soden; Jim Freeth; Roger R Beerli; Ulf Grawunder; Michael Hudecek; Christoph Rader
Journal:  J Mol Biol       Date:  2017-08-14       Impact factor: 5.469

3.  Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules.

Authors:  Janine Dilchert; Martin Hofmann; Felix Unverdorben; Roland Kontermann; Sebastian Bunk
Journal:  Antibodies (Basel)       Date:  2022-05-10

4.  High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis.

Authors:  Derek M Mason; Cédric R Weber; Cristina Parola; Simon M Meng; Victor Greiff; William J Kelton; Sai T Reddy
Journal:  Nucleic Acids Res       Date:  2018-08-21       Impact factor: 16.971

5.  Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.

Authors:  Diana Klose; Mira Woitok; Judith Niesen; Roger R Beerli; Ulf Grawunder; Rainer Fischer; Stefan Barth; Rolf Fendel; Thomas Nachreiner
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 6.  From rabbit antibody repertoires to rabbit monoclonal antibodies.

Authors:  Justus Weber; Haiyong Peng; Christoph Rader
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

7.  Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.

Authors:  Michael R Dyson; Edward Masters; Deividas Pazeraitis; Rajika L Perera; Johanna L Syrjanen; Sachin Surade; Nels Thorsteinson; Kothai Parthiban; Philip C Jones; Maheen Sattar; Gordana Wozniak-Knopp; Florian Rueker; Rachael Leah; John McCafferty
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

8.  Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.

Authors:  Ina Hellmann; Lorenz Waldmeier; Marie-Christine Bannwarth-Escher; Kseniya Maslova; Fabian I Wolter; Ulf Grawunder; Roger R Beerli
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

9.  A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

Authors:  Lucia D'Amico; Ulrike Menzel; Michael Prummer; Philipp Müller; Mélanie Buchi; Abhishek Kashyap; Ulrike Haessler; Alexander Yermanos; Rémy Gébleux; Manfred Briendl; Tamara Hell; Fabian I Wolter; Roger R Beerli; Iva Truxova; Špíšek Radek; Tatjana Vlajnic; Ulf Grawunder; Sai Reddy; Alfred Zippelius
Journal:  J Immunother Cancer       Date:  2019-01-21       Impact factor: 13.751

10.  SPLICELECT™: an adaptable cell surface display technology based on alternative splicing allowing the qualitative and quantitative prediction of secreted product at a single-cell level.

Authors:  Christel Aebischer-Gumy; Pierre Moretti; Romain Ollier; Christelle Ries Fecourt; François Rousseau; Martin Bertschinger
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.